Exact Sciences Corp. develops cancer screening and diagnostic tests used before, during, and after a cancer diagnosis. Company news centers on established products such as Cologuard and Oncotype DX, as well as newer diagnostics including Cancerguard for multi-cancer early detection and Oncodetect for molecular residual disease and recurrence monitoring.
Recurring updates include clinical data presentations in breast cancer and multi-cancer detection, policy and coverage developments for diagnostic testing, precision oncology product milestones, material agreements, shareholder voting matters, capital-structure disclosures, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.